Icahn School of Medicine at Mount Sinai
New York, New York, United States
Hearn Jay Cho is an Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Multiple Myeloma Center of Excellence at the Mt. Sinai Tisch Cancer Institute and serves as Chief Medical Officer at the Multiple Myeloma Research Foundation (MMRF). Dr. Cho’s laboratory is investigating novel therapies for multiple myeloma in two areas. First, they are investigating immunologic therapies with a focus on using cutting edge genomic and immunologic assays to map the interaction between myeloma and the immune system in the tumor microenvironment. Second, Dr. Cho’s group discovered that two type I Melanoma Antigen Genes (MAGE), MAGE-A3 and MAGE-C1, play critical roles in conferring resistance to chemotherapy and inhibition of apoptosis in myeloma cells. Dr. Cho’s group is conducting biochemical and structural studies to identify novel pharmacologic strategies for inhibition of type I MAGE activity in myeloma.
Dr. Cho joined the Multiple Myeloma Research Foundation as Chief Medical Officer (CMO) in September 2019 where he oversees the clinical research program. Dr. Cho is responsible for developing the MMRF’s clinical research strategy and accelerating drug development programs. He also leads the Multiple Myeloma Research Consortium (MMRC), a group of leading academic centers dedicated to researching and advancing treatment options for multiple myeloma patients. In addition, Dr. Cho is one of the Principal Investigators for MMRF CureCloud® - the first-of-its-kind research study that includes free, at-home genomic testing—informing smarter treatment plans and accelerating precision medicine for all myeloma patients.
Disclosure information not submitted.
Thursday, October 20, 2022
10:15 AM – 12:10 PM
Thursday, October 20, 2022
11:35 AM – 11:50 AM
Thursday, October 20, 2022
11:50 AM – 12:10 PM
Thursday, October 20, 2022
1:40 PM – 1:55 PM